Alnylam Pharmaceuticals, Inc.
ALNY
$292.03
$7.192.52%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 350.45% | 226.90% | 124.92% | -283.68% | 30.60% |
| Total Depreciation and Amortization | -4.78% | -1.79% | 139.68% | 70.96% | 38.72% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 34.60% | 31.12% | 45.20% | -7.93% | 1.29% |
| Change in Net Operating Assets | -61.85% | -108.69% | -818.03% | -247.46% | -1,029.22% |
| Cash from Operations | 1,613.29% | 6,381.06% | 366.56% | -104.71% | -124.91% |
| Capital Expenditure | -136.37% | -71.24% | -9.90% | 31.55% | 50.61% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 288.70% | 699.57% | 276.11% | 67.97% | 135.59% |
| Cash from Investing | 360.14% | 473.44% | 238.08% | 61.15% | 119.69% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -34.50% | -17.47% | -17.80% | 28.26% | 149.30% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 97.13% | 28.64% | -1,512.09% | -324.06% | -163.78% |
| Cash from Financing | -207.14% | -203.07% | -205.00% | 0.35% | 101.29% |
| Foreign Exchange rate Adjustments | 57.69% | 329.25% | 80.73% | 551.88% | 252.99% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 104.48% | 348.83% | 480.05% | -53.52% | 3,174.45% |